Aspoxicillin | CAS#63358-49-6 | antibiotic

MedKoo Cat#: 585260 | Name: Aspoxicillin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aspoxicillin is classified under the β-lactam family of antibiotics and is a semisynthetic penicillin with a broad spectrum of antibacterial activities against Gram-positive and Gram-negative anaerobic bacteria.

Chemical Structure

Aspoxicillin

CAS#63358-49-6

Theoretical Analysis

MedKoo Cat#: 585260

Name: Aspoxicillin

CAS#: 63358-49-6

Chemical Formula: C21H27N5O7S

Exact Mass: 493.1631

Molecular Weight: 493.54

Elemental Analysis: C, 51.11; H, 5.51; N, 14.19; O, 22.69; S, 6.50

Price and Availability

Size	Price	Availability
50mg	USD 550.00	2 Weeks
100mg	USD 950.00	2 Weeks
200mg	USD 1,650.00	2 Weeks
500mg	USD 2,950.00	2 Weeks
1g	USD 4,250.00	2 Weeks
2g	USD 6,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

63358-49-6

Synonym

Aspoxicillin; TA 058; TA058; TA-058; Aspoxicilina; Aspoxicillan; Aspoxicilline

IUPAC/Chemical Name

(2S,5R,6R)-6-((R)-2-((R)-2-amino-4-(methylamino)-4-oxobutanamido)-2-(4-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

InChi Key

BHELIUBJHYAEDK-OAIUPTLZSA-N

InChi Code

InChI=1S/C21H27N5O7S/c1-21(2)15(20(32)33)26-18(31)14(19(26)34-21)25-17(30)13(9-4-6-10(27)7-5-9)24-16(29)11(22)8-12(28)23-3/h4-7,11,13-15,19,27H,8,22H2,1-3H3,(H,23,28)(H,24,29)(H,25,30)(H,32,33)/t11-,13-,14-,15+,19-/m1/s1

SMILES Code

O=C(N[C@H]1[C@]([H])(N([C@H]2C(O)=O)C1=O)SC2(C)C)[C@H](NC([C@@H](CC(NC)=O)N)=O)C3=CC=C(O)C=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 493.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Knöller J, Schönfeld W, Bremm KD, König W. Determination of aspoxicillin (TA-058) by high-performance liquid chromatography. Stability at different temperatures. Zentralbl Bakteriol Mikrobiol Hyg A. 1987 Jun;265(1-2):176-81. PubMed PMID: 3673331. 2: Fujii R, Meguro H, Kim B, Yonezawa H, Kawaoi T, Tajima T, Mashiko J, Nakazawa S, Niino K, Sato H, et al. [Pharmacokinetics and clinical effects of aspoxicillin in pediatric patients]. Jpn J Antibiot. 1987 Sep;40(9):1651-67. Japanese. PubMed PMID: 3694789. 3: Scheinin H, Havia T, Pekkala E, Huovinen P, Klossner J, Lehto H, Niinikoski J. Aspoxicillin versus piperacillin in severe abdominal infections--a comparative phase III study. J Antimicrob Chemother. 1994 Nov;34(5):813-7. PubMed PMID: 7706179. 4: Oshida T, Onta T, Nakanishi N, Matsushita T, Yamaguchi T. Activity of sub-minimal inhibitory concentrations of aspoxicillin in prolonging the postantibiotic effect against Staphylococcus aureus. J Antimicrob Chemother. 1990 Jul;26(1):29-38. PubMed PMID: 2211444. 5: Matsumoto K. [Review: New antimicrobial agent series XXII: Aspoxicillin]. Jpn J Antibiot. 1987 Jul;40(7):1221-42. Review. Japanese. PubMed PMID: 3316732. 6: Yura J, Shinagawa N, Ishikawa S, Sakabe T, Iwai S, Sato T, Sakai K, Fujimoto M, Ueda T, Orita K, et al. [Comparative clinical study of aspoxicillin and sulbenicillin in postoperative wound infections]. Jpn J Antibiot. 1985 Sep;38(9):2417-43. Japanese. PubMed PMID: 3852899. 7: Mochizuki Y, Ohkubo H, Ito S, Mikawa H. [Clinical evaluation of aspoxicillin in children]. Jpn J Antibiot. 1985 Jul;38(7):1846-52. Japanese. PubMed PMID: 3851858. 8: Ueno K, Watanabe K, Bunai M, Kobayashi T, Aoki M, Maezawa I, Sakuma Y, Yoshida H, Yamaguchi T. Effect of aspoxicillin on anaerobic bacteria. Jpn J Antibiot. 1985 Jun;38(6):1516-28. PubMed PMID: 3850132. 9: Nakai K, Tokushima T, Hirota Y, Nagamatsu M, Takeda K, Mizobe M, Takai C. [Pharmacokinetic study on aspoxicillin transfer into pulmonary and tracheal tissues]. Jpn J Antibiot. 1993 May;46(5):367-73. Japanese. PubMed PMID: 8326676. 10: Kim B, Meguro H, Mashiko J, Yonezawa H, Kawaoi T, Tajima T, Fujii R. [Clinical evaluation of a new parenteral penicillin, aspoxicillin, in children]. Jpn J Antibiot. 1985 Jul;38(7):1835-45. Japanese. PubMed PMID: 4068222. 11: Matsumoto K, Shishido H, Uzuka Y, Nagatake T, Yamamoto M, Sakuma Y, Maezawa I, Yamaguchi T. [Safety and pharmacology of aspoxicillin in healthy volunteers]. Jpn J Antibiot. 1985 Oct;38(10):2699-715. Japanese. PubMed PMID: 4078992. 12: Sato T, Ueda K, Kuroiwa T. [A clinical evaluation of aspoxicillin in children]. Jpn J Antibiot. 1985 Jul;38(7):1944-50. Japanese. PubMed PMID: 4068227. 13: Geyer J, Höffler D, Koeppe P. Pharmacokinetics of aspoxicillin in subjects with normal and impaired renal function. Arzneimittelforschung. 1988 Nov;38(11):1635-9. PubMed PMID: 3214450. 14: Matsushita T, Kouyama K, Yamaguchi T. [Bactericidal activity of aspoxicillin in an in vitro model simulating human serum levels]. Jpn J Antibiot. 1985 Jul;38(7):1819-26. Japanese. PubMed PMID: 3906168. 15: Chimura T, Hirayama T, Oda T, Saito N, Sato S, Numazaki M. [A clinical study on the efficacy of ceftazidime and aspoxicillin in chorioamnionitis. Abdominal Infections Research Group]. Jpn J Antibiot. 1994 Sep;47(9):1210-8. Japanese. PubMed PMID: 7990262. 16: Yoshimura H, Ishimaru M, Endoh YS, Kojima A. Antimicrobial susceptibility of Pasteurella multocida isolated from cattle and pigs. J Vet Med B Infect Dis Vet Public Health. 2001 Sep;48(7):555-60. PubMed PMID: 11666039. 17: Yamaki K, Suzuki R, Taki F, Takagi K, Satake T, Mizuno K, Baba K, Aihara H, Mori M, Yamada K, et al. [A clinical study of combined therapy of aspoxicillin and ceftazidime on intractable respiratory infections]. Jpn J Antibiot. 1992 Oct;45(10):1282-94. Japanese. PubMed PMID: 1479680. 18: Yamaguchi T, Ishii N, Tani K, Matsushita T, Matsumoto K. Therapeutic effect of aspoxicillin on experimental pneumonia with Klebsiella pneumoniae in mice. Drugs Exp Clin Res. 1989;15(6-7):291-6. PubMed PMID: 2686954. 19: Wagatsuma M, Seto M, Miyagishima T, Kawazu M, Yamaguchi T, Ohshima S. Synthesis and antibacterial activity of asparagine derivatives of aminobenzylpenicillin. J Antibiot (Tokyo). 1983 Feb;36(2):147-54. PubMed PMID: 6833130. 20: Chimura T, Ise H, Misawa H. [In vitro study on efficacy of combination use of aspoxicillin and beta-lactam preparations (ceftazidime, cefmetazole and aztreonam) against bacteria isolated from abdominal infections]. Jpn J Antibiot. 1992 Jul;45(7):763-73. Japanese. PubMed PMID: 1522668.